× Industry Reports Services Press Release Contact us About us

Europe Monoclonal Antibodies Market Forecast 2027 By End-use (Hospitals, Clinics), By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), Research Report, Country Outlook (Germany, UK, France, Spain, Italy, Denmark, Sweden, Poland, The Netherlands, Belgium, Romania, Czech Republic), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: July 2021 | Publisher: Graphical Research Report ID: GR1895 | Delivery : PDF  Request Free Sample

Europe Monoclonal Antibodies Market size surpassed USD 44 billion in 2020 and is predicted to register a growth of over 13.3% from 2021 to 2027.

Growing prevalence of rare, infectious, and chronic diseases, will drive the product demand. For instance, in 2016, about 1.2 million people died due to cancer in EU-27 countries. As per the GLOBOCAN database 2020, the region accounts for around 22% of the total cancer cases worldwide. Significant portion of approved monoclonal antibodies are indicated for cancer treatment therapies.

Europe Monoclonal Antibodies Market

Get more details on this report - Request Free Sample PDF

The manufacturers and innovative biopharmaceutical companies are progressively focusing on product development. Emphasis on product innovation has resulted in increasing number of approvals for several therapeutic applications including blood disorders, cancer, cardiovascular diseases autoimmune diseases, and infectious diseases, among others. For instance, in March 2021, Roche reported positive clinical outcomes in Phase III studies for its cocktail of investigational antibodies Casirivimab and Imdevimab that will reduce the risk of hospitalisation or death in COVID-19 patients. The approvals will further allow the company to expand studies to receive regulatory approval.

The incidence of COVID-19 is expected to have positive impact on monoclonal antibodies industry with its potential application in minimizing infection severity and risk of mortality. Industry players are continuously developing new mAb therapies in collaboration with private as well as government organization to reduce or eliminate mortality risk in COVID-19 patients.

Europe Market, By Type

Humanized mAbs segment revenue was around USD 14 billion in 2020. Numerous product launches and improved regulatory support will boost the segment growth. In addition, humanized monoclonal antibodies are approved for treatment of several therapeutic applications of cancer including breast cancer, lung cancer, melanoma, and stomach cancer, among others. Some humanized mAbs bind directly to the C-erB2 protein (HER2) that is considered as effective treatment of breast cancer.

Europe Market, By Application

Infectious disease segment is anticipated to expand at 14.1% CAGR during the forecast period. Rising incidence of various infectious diseases including the COVID-19 has augmented the product discovery and development of monoclonal antibody therapies. Over 50 monoclonal antibodies against SARS-CoV-2 are in development phase that will lead to launch of several products in near future.

Europe Market, By End-use

Clinics held more than 18% market share in 2020. Increase in number of patient visits in these settings is contributing to high demand for therapeutic medicines. Further, the expanding network of clinics in developed as well as emerging economies broadens the accessibility and offers convenience to the patients. Moreover, awareness regarding innovative therapeutics among clinicians and presence of skilled personnel will contribute to segment revenue.

Europe Market, By Country

Germany monoclonal antibodies market accounted for 18% revenue share in 2020, attributed to business expansion of some leading industry players with strong product demand in the country. Along with disease prevalence, high treatment spending ability on advanced therapies will benefit the market size. Additionally, continuous technological advancements, improving accessibility and rising disposable income will influence the industry growth.

Competitive Industry Landscape

Some of the notable players involved in the Europe market include AbbVie Inc., Bristol Myers Squibb, Amgen, F. Hoffmann-La Roche, and Novartis AG.

These industry participants are undertaking various strategic initiatives to expand their geographic presence and product reach. For instance, in September 2020, Eli Lilly and Company announced collaboration with Amgen for expansion of antibody manufacturing and distribution capacity for COVID-19 therapies. This strategic alliance has helped the company to continue market distribution of its products.
 

Frequently Asked Question(FAQ) :

The market for monoclonal antibodies in Europe garnered more than USD 44 billion in annual revenue in 2020 and should register gains at over 13.3% CAGR up to 2027.
The industry size for Humanized monoclonal antibodies in Europe was estimated to be worth USD 14 billion in 2020.
Infectious disease segment could grow at a 14.1% CAGR over 2021-2027 due to the rising occurrence of infectious diseases including COVID-19 is accelerating product discovery and development.
Germany held more than 18% revenue share of European industry in 2020.
The market for monoclonal antibodies in Europe players such as AbbVie Inc., F. Hoffmann-La Roche, Novartis AG and others are progressively focusing on product development to expand market presence and product reach.

Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]